New study to reveal if more aggressive brain tumor surgery saves lives
NCT ID NCT07197086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 50 adults with glioblastoma, an aggressive brain cancer, to see how the amount of tumor removed during surgery affects how long they live. All patients will receive standard radiation and chemotherapy after surgery. The goal is to better understand which surgical approach leads to the best outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict outcomes for glioblastoma patients and refine surgical decisions.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve survival. Results may not apply to all patients due to the small size (50 people).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (≥18 years) with histologically confirmed glioma (WHO grades 2-4)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients (≥18 years) with histologically confirmed glioma (WHO grades 2-4) Underwent neurosurgical resection (gross total, subtotal, or biopsy only) Received postoperative radiotherapy with or without concurrent and/or adjuvant temozolomide Available pre- and post-operative imaging for EOR assessment Complete medical records and follow-up data Exclusion Criteria: * Recurrent gliomas at presentation Incomplete treatment (e.g., abandonment, death before adjuvant therapy) Lack of imaging or follow-up data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental therapy aims to turn brain tumors against themselves
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients
- Breathing CO2 during brain scans could reveal hidden tumor disruption
- AI reads tumor slides to match cancer patients with trials